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Abstract. Helminth infections can potentially confer protection against metabolic disorders, possibly through immuno-
modulation. In this study, the baseline prevalence of lymphatic filariasis (LF) among subjects without (N = 236) and
with (N = 217) coronary artery disease (CAD) was examined as part of the Chennai Urban Rural Epidemiological
Study (CURES). The prevalence of LF was not significantly different between CAD− and CAD+ subjects. The
LF antigen load and antibody levels indicated comparable levels of infection and exposure between the groups. Within
the CAD group, LF+ and LF− subjects had no significant difference in the intimal medial thickness and high-sensitivity
C-reactive protein values. However, LF infection was associated with augmented levels of tumor necrosis factor-a and
interleukin-6 among CAD+ subjects. The LF infection had no effect on serum adipocytokine profile. In conclusion,
unlike type-2 diabetes, there is no association between the prevalence of LF and CAD and also no evidence of protective
immunomodulation of LF infection on CAD in the Asian Indian population.
INTRODUCTION
Coronary artery disease (CAD) and stroke are the largest
causes of death worldwide and one of the main contributors
to disease burden. Between 1990 and 2020 these diseases are
expected to increase by 120% for women and 137% for men
in developing countries as compared with 30–60% in devel-
oped countries.1 Trends show that there has been a signif-
icant decline in the proportion of deaths from infectious
diseases (22–16%), whereas mortality from CAD has increased
(21–25%) in developing countries, which is largely a reflection
of industrialization/globalization.2 Inflammatory changes in
the vessel wall plays an important role in the pathogenesis
of atherosclerosis/CAD.3 Although the main underlying
mechanism of atherosclerosis/CAD is attributed to a chronic
low-grade inflammatory reaction, the spectrum of etiological
conditions is far from being fully elucidated. Both viruses and
bacteria have been suggested to augment various stages of
atherosclerosis development, although a clear pathogenic link
between infection and CAD remains debatable.4,5
Helminth infections represent the other extreme of the
spectrum wherein, their immunomodulatory effect can in fact
dampen inflammation and can potentially confer protection
against metabolic diseases.6 Filarial infections are an impor-
tant group of helminth infections, endemic in South Asian
countries where the high-risk ethnic population for CAD
resides. The three lymph-dwelling filariaeWuchereria bancrofti,
Brugia malayi, or Brugia timori are the major causative agents
of lymphatic filariasis (LF).7 However, there is no data avail-
able on the prevalence of LF among people with CAD. Pre-
viously, we have reported a decreased prevalence of LF among
both type-18 and type-29 diabetic subjects, in South Indians.
In this study, the prevalence and influence of LF on CAD was
examined as part of an ongoing, epidemiological study in
Chennai, Southern India.
MATERIALS ANDMETHODS
Ethics statement. Institutional ethical committee approval
from the Madras Diabetes Research Foundation Ethics Com-
mittee was obtained (Reference no. MDRF-EC/SOC/2009//05)
and written informed consent was obtained from all the
study subjects.
Study subjects. Study subjects were recruited from the
Chennai Urban Rural Epidemiology Study (CURES), an
ongoing epidemiological study conducted on a representative
population of Chennai, India (Figure 1). The methodology of
the study and the prevalence of diabetes and CAD in Chennai
have been published elsewhere.10 Briefly, in phase 1 of the
urban component of CURES, 26,001 individuals were recruited
based on a systematic random sampling technique. Fasting cap-
illary blood glucose was determined using the OneTouch Basic
glucometer (Lifescan, Johnson & Johnson, Milpitas, CA) in all
subjects. Details of the sampling are described on our website
(http://www.drmohansdiabetes.com/bio/WORLD/pages/pages/
chennai.html). In phase 2, detailed studies of diabetic compli-
cations, including nephropathy, neuropathy, retinopathy, and
cardiomyopathy were performed, and in phase 3, every 10th
individual in phase 1 was invited to participate in more detailed
studies. As part of the questionnaire, the socio-economic
details of the study participants were collected and recorded.
CAD subjects. Coronary artery disease was diagnosed based
on positive medical history (documented myocardial infarc-
tion, angina pectoris, and coronary artery bypass graft) and/or
ischemic changes on a conventional 12-lead electrocardiogram
that included ST-segment depression (Minnesota codes 1-1-1
to 1-1-7) or Q-wave changes (Minnesota codes 4-1 to 4-2).11
For this study, the following groups were randomly selected
from phase 3 of CURES, group 1- 236 control subjects without
coronary artery disease (CAD−) and group 2- 217 subjects with
coronary artery disease (CAD+). The CAD− and CAD+
patients were age and gender matched to avoid the influence
of these confounding factors. The filarial status of these individ-
uals was not known at the time of recruitment into the study.
Both type-1 and type-2 diabetic subjects were excluded from
both groups. All the samples used in this study were collected
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from 2003 to 2004. None of the study subjects had received
any treatment of LF at the time of recruitment (Figure 1).
Sample size calculation. Initially, 100 CAD− and 100 CAD+
subjects were screened for LF. Out of 100 CAD−, 8 were LF+
(8%) and out of 100 CAD+, 6 were LF+ (6%). Based on these
preliminary results, with a confidence interval of 95%, an esti-
mated P value of < 0.05, and a power of 80%, the sample-size
estimates were 200 for both CAD− and CAD+ subjects.
Anthropometric and biochemical parameters. Anthropo-
metric measurements including height, weight, and waist cir-
cumference, were obtained using standardized techniques.
The body mass index was calculated as the weight in kilo-
grams divided by the square of height in meters. Fasting
plasma glucose (glucose oxidase-peroxidase method), serum
cholesterol (cholesterol oxidase-peroxidase- amidopyrine
method), serum triglycerides (glycerol phosphate oxidase-
peroxidase-amidopyrine method), high density lipoprotein
cholesterol (HDL-C) (direct method-polyethylene glycol-
pretreated enzymes), and creatinine (Jaffe’s method) weremea-
sured using a Hitachi-912 Autoanalyzer (Hitachi, Mannheim,
Germany). The intra- and inter-assay coefficient of variation
for the biochemical assays ranged between 3.1% and 5.6%.
Glycated hemoglobin (HbA1c) was estimated by high pres-
sure liquid chromatography using a variant machine (Bio-
Rad, Hercules, CA). The intra- and inter-assay coefficient of
variation of HbA1c was < 5%. The plasma concentrations of
high-sensitivity C-reactive protein (hsCRP) were measured by
a highly sensitive nephelometric assay using a mono-clonal
antibody to CRP coated on polystyrene beads (Dade Behring,
Marburg, Germany).12 The intra- and the inter-assay coeffi-
cients of variation for hsCRP were 4.2% and 6.8%, respec-
tively, and the detection limit was 0.17 mg/L.
Detection of bancroftian LF. To quantify the filarial antigen
levels and prevalence, sera were analyzed using theW. bancrofti
Og4C3 antigen capture enzyme-linked immunosorbent assay
(ELISA) (Tropbio, James Cook University, Townsville,
Queensland, Australia) according to the manufacturer’s instruc-
tions.8,9 A cut-off value of 128 antigen units was considered
positive for LF.
Determination of anti-filarial antibody titer. The serum
antibody (IgG and IgG4) titer against Brugia malayi antigen
(BmA) was determined by ELISA as described previously.8,9
Measurement of carotid intima-media thickness. The method
used for measurement of carotid intima-media thickness (IMT)
has been previously described.11 The IMT of the carotid arteries
was determined using a high-resolution B-mode ultrasonogra-
phy system (Logic 400; GE, Milwaukee, WI) having an elec-
tric linear transducer mid-frequency of 7.5 MHz. The images
obtained were recorded and photographed. The scanning was
done for an average of 20 min. The IMT as defined by Pignoli
and Longo13 was measured as the distance from the leading
edge of the first echogenic line to the second echogenic line.
Six well-defined arterial wall segments were measured in the
right carotid system: the near wall and far wall of the proximal
10 mm of the internal carotid artery, the carotid bifurcation
beginning at the tip of the flow divider and extending 10 mm
below this point, and the arterial segment extending 10 mm
below the bifurcation in the common carotid artery. Essential
in defining these segments is the identification of a reliable
longitudinal marker, which is the carotid flow divider as per-
formed in SECURE (Study to Evaluate Carotid Ultrasound
Changes in Patients Treated with Ramipril and Vitamin E).14
This method was standardized at our center and to check
quality, the video tapes were sent to Hamilton, Canada, the
central laboratory for SECURE.
Determination of serum cytokines. The levels of pro-
inflammatory cytokines interleukin (IL)-1b, IL-6 and tumor
necrosis factor-a (TNF-a) in the undiluted serum were
measured using a Bioplex multiplex cytokine assay system
(Bio-Rad). The detection limit for the assays were IL-1b
−3 pg/mL, IL-6- 2 pg/mL, TNF-a-5 pg/mL, and IL-10- 2 pg/mL.
Determination of serum adipocytokines. The levels of
adipocytokines (adiponectin, adipsin, leptin, resistin, visfatin,
and Plasminogen Activator Inhibitor/PAI-1) in the undiluted
serum were measured using a Bioplex multiplex cytokine
assay system (Bio-Rad).The detection limit for the adipo-
cytokines were adiponectin 5,244 pg/mL, adipsin 3,380 pg/mL,
leptin 2,707 pg/mL, resistin 527 pg/mL, visfatin 8,181 pg/mL,
and PAI-1-911 pg/mL.
Statistical analysis. All statistical analyses were performed
using SPSS software (version 15.0.0; Chicago, IL). The preva-
lence of filarial infections among the different groups was
compared by Pearson’s Chi-square (c2) test. The antigenic load
and antibody titers and serum cytokines were analyzed by the
Mann Whitney U test. The clinical and biochemical character-
istics of the study subjects were compared using the Student’s
t test. P values < 0.05 were considered significant.
RESULTS
Study population characteristics. The baseline clinical and
biochemical features of the CAD− and CAD+ study subjects
are shown in Table 1. Except for hsCRP and IMT, which were
higher in the CAD+ group, none of the other parameters
reached statistical significance.
Prevalence of LF, circulating filarial antigen levels, and
anti-filarial antibody titer among CAD subjects. The preva-
lence of LF was found to be 10.4% in the CAD− and 8.7% in
CAD+ groups, respectively, and the difference was not sig-
nificant. To examine more quantitatively the association of
Table 1
Demographics and clinical characteristics of the study subjects*
Parameters
Control
(N = 236)
CAD
N = (115) P
Age (years) 51.7 ± 12.2 51.5 ± 14.3 0.854
Gender (M/F) 180/107 82/31 0.079
Body mass index (Kg/m2) 22.7 ± 4.2 22.7 ± 3.9 0.886
Systolic blood
pressure (mm/Hg)
123.0 ± 21.2 124.9 ± 23.0 0.931
Diastolic blood
pressure (mm/Hg)
76.4 ± 11.3 76.4 ± 10.9 0.990
Fasting plasma glucose (mg/dL) 85.2 ± 8.1 86.7 ± 9.6 0.177
Glycated hemoglobin (%) 5.50 ± 0.36 5.50 ± 0.35 0.787
HOMA-IR 1.84 ± 1.16 1.86 ± 1.07 0.706
Serum cholesterol (mg/dL) 188.6 ± 36.6 192.8 ± 50.3 0.656
Serum triglyceride (mg/dL) 123.4 ± 60.5 117.8 ± 53.4 0.459
High-density
Lipoprotein (HDL) (mg/dL)
45.5 ± 10.8 45.8 ± 9.5 0.648
Low-density
Lipoprotein (LDL) (mg/dL)
118.5 ± 31.4 123.3 ± 44.4 0.486
Serum creatinine (mg/dL) 0.87 ± 0.18 0.97 ± 1.3 0.103
Microalbuminuria (mg/dL) 20.6 ± 44.1 12.8 ± 18.9 0.543
hsCRP (mg/L) (geo mean) 1.4 3.3 < 0.001
Carotid intimal medial
thickness (IMT) (mm)
0.71 ± 0.12 0.85 ± 0.33 < 0.001
*CAD = coronary artery disease; HOMAR-IR = homeostasis model of assessment-insulin
resistance; hsCRP = high-sensitivity C-reactive protein.
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CAD and LF, we measured the serum circulating filarial anti-
gen levels among the filarial positive subjects. There was
no significant difference in the absolute levels of circulating
filarial antigen in the LF-infected individuals, between the
CAD−LF+ (geometric mean 1,374 [range: 138–32,768]) and
CAD+LF+ (1,378 [193–14,926]) groups. We next quantified
the serum anti-filarial antibody levels among the LF-infected
subjects. Although the mean immunoglobulin G (IgG) (Geo
mean 86.32 [range: 6.3–1,520.0] versus 54.79 [15.17–175.4])
and IgG4 (Geo mean 51.72 [range: 1.25–1878.0] versus 45.29
([8.96–6926.0]) levels were slightly lower in the CAD+LF+
group, this did not reach statistical significance. No difference
in the socio-economic status was noted between the CAD− and
CAD+ subjects included in this study (Supplementary Table 1).
Effect of LF on IMT and hsCRP. The IMT is a good measure
of atherosclerosis, whereas hsCRP serves as an inflammatory
marker. The IMT and hsCRP values were significantly elevated
in the CAD+ group compared with CAD− group (Table 1).
However, within the CAD+ group, there was no significant
difference in IMT (0.76 [0.5–2.1] versus 0.76 [0.6–1.3]) and
hsCRP values (2.29 [0.15–12.0] versus 2.45 [0.16–12.0]) between
LF+ and LF− subjects.
Serum cytokine analysis in subjects with CAD and/or LF.
Because pro-inflammatory cytokines are known to be associ-
ated with the development of CAD, we next measured the
levels of these cytokines in the serum of CAD+LF− and
CAD+LF+ subjects. As shown in Figure 2, TNF-a (Geometric
mean [GM] [RANGE]- CAD+LF−- 2.8 (1–18) pg/mL and
CAD+LF+- 6.8 [1.32–1,290] pg/mL; P = 0.0300) and IL-6 (GM
[RANGE]- CAD+LF−- 2.2 [0.23–230] pg/mL and CAD+LF+-
7 [0.06–850] pg/mL; P = 0.0102) levels were significantly ele-
vated in the CAD+LF+ group compared with CAD+LF− group;
whereas IL-1b and IL-10 showed no significant difference.
Serum adipocytokine analysis in subjects with CAD and/or
LF.We next quantified serum adipocytokine levels in subjects
with CAD and/or LF (Figure 3). No significant difference
was seen in the serum levels of adiponectin, adipsin, leptin,
resistin, PAI-1, and visfatin between the groups. The serum
adipocytokine profile was unaffected by the LF status.
DISCUSSION
The hypothesis that parasitic helminths may protect against
the development of allergic and autoimmune processes has
spurred an interest in examining the protective effects of
helminths and their immunomodulatory products in these
processes (hygiene hypothesis).15 In addition, clinical trials
examining the effect of helminth products on disease severity
in autoimmune diseases16 have shown promising results. The
safety of these products for use as therapeutic agents has also
Figure 1. Flow chart depicting the various stages of sample selection during various phases of Chennai Urban Rural Epidemiological Study
(CURES). In phase 1 of the urban component of CURES, 26,001 individuals from 46 wards representing 10 zones of Chennai were recruited based
on a systematic random sampling technique and fasting blood glucose was determined. In phase 2, detailed studies of diabetic complications,
including nephropathy, neuropathy, and retinopathy were performed, and in phase 3, every 10th individual in phase 1 was invited to participate in
more detailed studies, including screening for coronary artery disease. All participants for this study were recruited from phase 3 of CURES.
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been documented.17 However, little is known about the associ-
ation of helminth infections with metabolic diseases of inflam-
matory origin. Previously, we have shown reduced prevalence
of LF among T2DM subjects and have also provided evidence
for the possible involvement of filarial-mediated immune modu-
lation in possibly conferring protection against T2DM (extended
hygiene hypothesis).9 Recently, our findings were confirmed
in a murine model of high-fat diet-induced insulin resistance,
infectedwith the intestinal helminth,Nippostrongylus brasiliensis.18
On the basis of these findings, we looked at the prevalence of
LF among our CAD subjects. We found no significant differ-
ence in the prevalence of LF among the CAD− and CAD+
subjects. There was also no significant difference in the serum
antigen levels (which is an indicator of active infection) and
anti-LF antibody titers (an indicator of exposure). To avoid
the confounding effect of diabetes, subjects who had diabetes
(both type-1 and type-2) were excluded from this study. In
addition, differences in socioeconomic status, another potential
confounding factor, was also shown to be noncontributory in
the context of the present study (see Supplementary Table 1),
because no differences were seen in socioeconomic status
between the CAD− and CAD+ groups.
During the past two decades, work conducted at many
laboratories has defined CAD as a chronic inflammatory
disease.19 Studies in mice and humans have shown that
inflammation promotes all phases of atherosclerosis, includ-
ing initiation, progression, and disruption of the atheroma.
Indeed, increased levels of serum hsCRP, an acute phase
protein, is the single definitive risk factor for cardiovascular
events.20 Even though the inflammatory origin of CAD has
now been well established the link between infections and
inflammation seen in CAD is poorly understood. Only recently
have studies examining the interaction of metabolic and infec-
tious diseases gained importance.21 The earliest of these reports
showed some association between severe respiratory tract infec-
tions and CAD.22 Apart from respiratory tract infections, oral
infections,23 gut infections (especiallyHelicobacter pylori infec-
tion),24 and urinary tract infections have also been associated
with CAD. In general, evidence suggests that the infections
that induce systemic inflammation promote CAD. In contrast
to most viral and bacterial diseases, which are known to pro-
mote inflammation, helminth infections are known to down-
regulate inflammation by immunomodulation15; until now, the
effect of filarial infections on CAD has not been studied, even
in animal models. In this study, the prevalence of LF was found
to be comparable between CAD− and CAD+ groups. In terms
of humoral responses against filariasis, both subjects with active
filarial infection and those who are exposed but resistant to
infection mount vigorous humoral response to parasite antigen,
most specifically, IgG antibody.25 Thus, BmA-specific IgG can
Figure 2. Serum cytokine levels in lymphatic filariasis (LF)-negative and LF-positive CAD subjects. Serum levels of tumor necrosis factor-a
(TNF-a) (A), interleukin (IL)-6 (B), IL-1b (C), and IL-10 (D) are shown. Each dot represents an individual patient, with the geometric mean
represented by the horizontal bars. P values were calculated by Mann-Whitney U test. P < 0.05 was considered significant.
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be considered to be a good surrogate marker for exposure. The
comparable antigen and IgG levels between the groups indi-
cate similar rates of exposure and infection between these sub-
jects, because they come from the endemic area and are of
comparable socio-economic status (data not shown). Further-
more, LF infection had no effect on CAD-specific markers like
IMT and hsCRP.
In our previous study, LF+ diabetic subjects had significantly
lower levels of serum pro-inflammatory cytokines (TNF-a and
IL-6), compared with LF− diabetic subjects. In contrast to
diabetes, in CAD, the presence of LF was associated with a
significant increase in serum TNF-a and IL-6 but not IL-1b
and IL-10 levels. Therefore, filarial infections appear to aug-
ment inflammation in CAD subjects. It is important to note
that inflammation seen in metabolic diseases like obesity,
hypertension, insulin resistance, and CAD are not necessarily
mediated by the same group of cytokines and scant attention
has been paid toward deciphering disease-specific inflammation
among metabolic disorders. Therefore, LF-mediated immuno-
modulation could possibly have different effects depending
Figure 3. Serum adipocytokine levels in lymphatic filariasis (LF)-negative and LF-positive CAD subjects. Serum levels of Adiponectin (A),
Adipsin (B), Leptin (C), Resistin (D), PAI-1 (E), and Visfatin (F) are shown. Each dot represents an individual patient, with the geometric mean
represented by the horizontal bars. P values were calculated by Mann-Whitney U test. P < 0.05 was considered significant.
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upon the nature of the underlying inflammation.26 Finally,
adipocytokines play an important role in glucose, lipid, and
lipoprotein metabolism, and in coagulation and arterial inflam-
mation.27 Several studies have evaluated the association of
adipokines with CAD and have provided mixed results.28 In
general, low levels of serum adiponectin have been associated
with diabetes and CAD but this was dependent upon the
obesity status.29 In this study the adipocytokine levels were
not altered by LF infection among CAD+ subjects. However,
our study clearly indicates that helminth-mediated immuno-
modulation need not be universal but might actually be disease/
inflammation specific.
Limitation. This study suffers from the limitation of being
a cross-sectional study and therefore not providing a direct
cause and effect mechanism.
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